David
Co-Founder
The article, "The Role of Mesalamine in Crohn's Disease" by Cosimo Prantera and Alessandro Armuzzi is found on pages 643-647 of the book, "Advanced Therapy in Inflammatory Bowel Disease" and is supported by 15 references. For any of you interested in the deeper medical side of Crohn's Disease, this book is fantastic. This thread will contain information I feel is useful in the article and I also open it up for discussion.
Mesalamine (Mesalazine - 5ASA) is commonly used for patients with Ulcerative Colitis but its use in patients with Crohn's Disease is quite controversial. The authors of this article explore its use in Crohn's Disease.
- There are doubts about how well it works for people with Crohn's Disease but many GIs use it because it works well for Ulcerative Colitis and is relatively safe.
- Mesalamine acts topically. It's like putting lotion on your skin but you're putting it on your intestines. As Crohn's Disease can extend through every layer of the gut, it doesn't make sense that Mesalamine would work that well. Conversely, Ulcerative Colitis only affects surface mucosa so it can work well for it.
- 5-ASA is the active therapeutic moiety of sulfasalazine. Sulfasalazine is split by colonic bacteria into 5-ASA and Sulfapyridine
Formulations, Solubility, and Area of Release
- Asacol is mesalamine that dissolves at pH 7 and releases in the terminal ileum and colon.
- Asacol microgranular is mesalamine that is encapsulated is small granules and dissolves at pH 7 and is released in the terminal ileum and right colon.
- Claversal, Mesasal, and Salofalk are mesalamine that dissolve at pH 6 and are released in the jejunum, ileum, and colon.
- Rowasa is mesalamine that dissolves at pH 6 and is released in the jejunum, ileum, and colon.
- Pentasa is mesalamine that is time released and released throughout the intestinal tract.
- Salazopyrin is Sulfasalazine that is dissolved by colonic bacteria and released in the colon.
- Dipentum is Olsalazine dissolved by colonic bacteria and released in the colon.
Treatment with Mesalamine
- Early studies of 1-2g of Pentasa showed a lack of efficacy. 4g trials had conflicting results.
- A trial with 2g of Olsalazine showed no therapeutic affect and 22% of patients withdrew due to diarrhea.
- Salofalk versus corticosteroids showed steroids to be much more affective.
- In a study of patients with mild to moderate disease in the terminal ileum, patients were assigned asacol, asacol microgranules, or methylprednisone. Remission rates were about the same across the group.
- Pentasa versus Budesonide - Pentasa was less effective than Budesonide but as effective as 1g of ciproflaxin in inducing clinical remission.
Mesalamine for Maintaining Remission After Treatment with Other Medications
- In three studies with Pentasa in trying to maintain remission after treatment with other medications, there was no statistical significant between it and placebo.
- Two our of three studies with Claversal were negative.
- Salofalk and Asacol showed slight improvements over placebo.
- A Cochrane review (very strict) of 1420 patients found there was no improvement over placebo and didn't feel further study was justified. Ouch.
- Another study of 1305 patients found some benefit over placebo. A 6% benefit.
Mesalamine for Maintaining Remission After Surgery
- New lesions appear at the anastomotic site in 60% of patients within 1 year.
- In five trials one reached statistical significance and showed a 10% reduction in relapse rate.
- Six other trials showed an 18% reduction in reappearance of lesions.
Other Stuff
- Mesalamine in conjunction with Azathioprine or 6-MP seems to increase 6-TGN levels which can lead to Leukopenia. However, the benefit there is it could be used to reach the therapeutic level of 6-TGN if it is monitored.
Conclusion
The author states, "Currently, the evidence is in favor of maintaining mesalamine in the CD therapeutic armamentarium, despite criticism from some authors". Reasons include:
- It's pretty safe.
- Crohn's Disease is diverse so it could have thrown off studies.
- Sometimes CD is just in the mucosa such as early in disease history.
- Different drugs work in different locations
- Mesalamine can help Azathioprine/6-MP reach therapeutic levels.
- Higher doses may be more effective.
- Mesalamine may reduce the risk of cancer and is supported (and refuted) by a couple studies.
Mesalamine (Mesalazine - 5ASA) is commonly used for patients with Ulcerative Colitis but its use in patients with Crohn's Disease is quite controversial. The authors of this article explore its use in Crohn's Disease.
- There are doubts about how well it works for people with Crohn's Disease but many GIs use it because it works well for Ulcerative Colitis and is relatively safe.
- Mesalamine acts topically. It's like putting lotion on your skin but you're putting it on your intestines. As Crohn's Disease can extend through every layer of the gut, it doesn't make sense that Mesalamine would work that well. Conversely, Ulcerative Colitis only affects surface mucosa so it can work well for it.
- 5-ASA is the active therapeutic moiety of sulfasalazine. Sulfasalazine is split by colonic bacteria into 5-ASA and Sulfapyridine
Formulations, Solubility, and Area of Release
- Asacol is mesalamine that dissolves at pH 7 and releases in the terminal ileum and colon.
- Asacol microgranular is mesalamine that is encapsulated is small granules and dissolves at pH 7 and is released in the terminal ileum and right colon.
- Claversal, Mesasal, and Salofalk are mesalamine that dissolve at pH 6 and are released in the jejunum, ileum, and colon.
- Rowasa is mesalamine that dissolves at pH 6 and is released in the jejunum, ileum, and colon.
- Pentasa is mesalamine that is time released and released throughout the intestinal tract.
- Salazopyrin is Sulfasalazine that is dissolved by colonic bacteria and released in the colon.
- Dipentum is Olsalazine dissolved by colonic bacteria and released in the colon.
Treatment with Mesalamine
- Early studies of 1-2g of Pentasa showed a lack of efficacy. 4g trials had conflicting results.
- A trial with 2g of Olsalazine showed no therapeutic affect and 22% of patients withdrew due to diarrhea.
- Salofalk versus corticosteroids showed steroids to be much more affective.
- In a study of patients with mild to moderate disease in the terminal ileum, patients were assigned asacol, asacol microgranules, or methylprednisone. Remission rates were about the same across the group.
- Pentasa versus Budesonide - Pentasa was less effective than Budesonide but as effective as 1g of ciproflaxin in inducing clinical remission.
Mesalamine for Maintaining Remission After Treatment with Other Medications
- In three studies with Pentasa in trying to maintain remission after treatment with other medications, there was no statistical significant between it and placebo.
- Two our of three studies with Claversal were negative.
- Salofalk and Asacol showed slight improvements over placebo.
- A Cochrane review (very strict) of 1420 patients found there was no improvement over placebo and didn't feel further study was justified. Ouch.
- Another study of 1305 patients found some benefit over placebo. A 6% benefit.
Mesalamine for Maintaining Remission After Surgery
- New lesions appear at the anastomotic site in 60% of patients within 1 year.
- In five trials one reached statistical significance and showed a 10% reduction in relapse rate.
- Six other trials showed an 18% reduction in reappearance of lesions.
Other Stuff
- Mesalamine in conjunction with Azathioprine or 6-MP seems to increase 6-TGN levels which can lead to Leukopenia. However, the benefit there is it could be used to reach the therapeutic level of 6-TGN if it is monitored.
Conclusion
The author states, "Currently, the evidence is in favor of maintaining mesalamine in the CD therapeutic armamentarium, despite criticism from some authors". Reasons include:
- It's pretty safe.
- Crohn's Disease is diverse so it could have thrown off studies.
- Sometimes CD is just in the mucosa such as early in disease history.
- Different drugs work in different locations
- Mesalamine can help Azathioprine/6-MP reach therapeutic levels.
- Higher doses may be more effective.
- Mesalamine may reduce the risk of cancer and is supported (and refuted) by a couple studies.